

Reference list – August 2023

CliniMACS® Cytokine Capture System (IFN-gamma)

Clinical Data

CMV

First-line Therapy With Donor-derived Human Cytomegalovirus (HCMV)–specific T Cells Reduces Persistent HCMV Infection by Promoting Antiviral Immunity After Allogenic Stem Cell Transplantation

Zhao XY, Pei XY, Chang YJ, Yu XX, Xu LP, Wang Y, Zhang XH, Liu KY, Huang XJ

(2019) Clin Infect Dis., 70: 1429-1437

Early Experience With CliniMACS Prodigy CCS (IFN-gamma) System in Selection of Virus-specific T Cells From Third-party Donors for Pediatric Patients With Severe Viral Infections After Hematopoietic Stem Cell Transplantation

Kállay K, Kassa G, Réti M, Karászi E, Sinkó J, Goda V, Stréhn A, Csordás K, Horváth O, Szederjesi A, Tasnády S, Hardi A, Kriván G

(2018) J Immunother., 41:158-163

Cytomegalovirus-Specific T-Cell Transfer for Refractory Cytomegalovirus Infection After Haploidentical Stem Cell Transplantation: The Quantitative and Qualitative Immune Recovery for Cytomegalovirus.

Pei XY, Zhao XY, Chang YJ, Liu J, Xu LP, Wang Y, Zhang XH, Han W, Chen YH, Huang XJ.

(2017) J Infect Dis.;216:945-956.

Effective treatment of refractory CMV reactivation after allogeneic stem cell transplantation with In Vitro-generated CMV pp65-specific CD8+ T-cell lines.

Meiji P, Jedema I, Zandvliet ML, van der Heiden PLJ, van de Meent M, van Egmond HME, van Liempt E, Hoogstraten C, Kruithof S, Veld S, Marijt WA, von dem Borne PA, Lankester AC, Halkes CJM, Falkenburg JHF

(2012) J. Immunther., 35:621-628

Adoptive transfer of pp-65 specific T-cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation.

Feuchtinger T, Opherk K, Bethge WA, Topp MS, Schuster FR, Weissinger, EM, Mohty M, Or R, Maschan M, Schumm M, Hamprecht K, Handgretinger R, Lang P, Einsele H

(2010) Blood,116:4360-7.

Adoptive T-cell therapy of a lung transplanted patient with severe CMV disease and resistance to antiviral therapy.

Brestrich G, Zwinger S, Fischer A, Schmück M, Röhmhild A, Hammer MH, Kurtz A, Uharek L, Knosalla C, Lehmkuhl H, Volk HD., Reinke P

(2009) J. Immunother.,32:932-40

Adoptive cellular therapy for cytomegalovirus infection following allogeneic stem cell transplantation using virus-specific T cells

Mackinnon S, Thomson K, Verfuerth S, Peggs K, Lowdell M
(2008) Blood Cells, Molecules, and Diseases 40: 63–67

Five donors-one recipient: modeling a mosaic of granulocytes, natural killer and T cells from cord blood and third-party donors.

Schöttker B, Feuchtinger T, Schumm M, Klinker E, Handgretinger R, Einsele H, Stuhler G
(2008) Nat. Clin. Pract. Oncol.; 5:29

EBV

Chronic Active Epstein-Barr Virus Infection controlled by allogeneic stem cell transplantation and EBV-specific T-cells.

Meedt E, Weber D, Bonifacius A, Eiz-Vesper B, Maecker-Kolhoff B, Delecluse S, Delecluse HJ, Lorenz M, Schwarz K, Meedt ST, Braess J, Herr W, Holler E, Edinger M, Wolff D.
Clin Infect Dis. 2023 Mar 8:ciad131.
doi: 10.1093/cid/ciad131.

Adoptive transfer of Epstein-Barr Virus (EBV) nuclear antigen 1–specific T cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem cell transplantation.

Icheva V, Kayser S, Wolff D, Tuve S, Kyzirakos C, Bethge W, Greil J, Albert H, Schwinger W, Nathrath M, Schumm M, Stevanovic S, Handgretinger R, Lang P, Feuchtinger T
(2012) J. Clin. Oncol., 31:39-48

Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells.

Moosmann A, Bigalke I, Tischer J, Schirrmann L, Kasten J, Tippmer S, Leeping M, Prevalsek D, Jaeger G, Ledderose G, Mautner J, Hammerschmidt W, Schende, DJ, Kolb HJ
(2010) Blood,115:2960-70.

ADV

Curative or pre-emptive adenovirus-specific
T cell transfer from matched unrelated or third party haploidentical donors after HSCT, including UCB transplantations: a successful phase I/II multicenter clinical trial.

Qian C, Campidelli A, Wang Y, Cai H, Venard V, Jeulin H, Dalle JH, Pochon C, D'aveni M, Bruno B, Paillard C, Vigouroux S, Jubert C, Ceballos P, Marie-Cardine A, Galambrun C, Cholle C, Urmes IC, Petitpain N., De Carvalho Bittencourt M Decot V, Reppel L, Salmon A, Clement L, Bensoussan, D
(2017) Journal of Hematology & Oncology 10:102

Adoptive T-cell therapy with hexon-specific T helper-1 cells as a treatment for refractory adenovirus infection after allogeneic stem cell transplantation.

Feucht J, Opherk K, Lang P, Kayser S, Hartl L, Bethge W, Matthes-Martin S, Bader P, Albert MH, Maecker-Kohlhoff B, Greil J, Einsele H, Schlegel PG, Schuster F, Kremens B, Rossig C, Gruhn B, Handgretinger R, Feuchtinger T
(2015) Blood.;125:1986-94.

BKV

Allogeneic BK Virus-Specific T-Cell Treatment in 2 Patients With Progressive Multifocal Leukoencephalopathy

Hopfner F, Möhn N, Eiz-Vesper B, Maecker-Kolhoff B, Gottlieb J, Blasczyk R, Mahmoudi N, Pars K, Adams O, Stangel M, Wattjes MP, Höglinger G, Skripuletz T
(2021) Neurol Neuroimmunol Neuroinflamm 8:e1020

BKV-specific T-cells in the treatment of severe refractory haemorrhagic cystitis after HLA-haploidentical haematopoietic cell transplantation.

Pello OM, Innes A, Bradshaw A, Finn SA, Uddin S, Bray E, Olavarria E, Apperley JF, Pavlu, J
(2017) EurJHeam, doi: 10.1111/ejh.12848

JCV

Progressive multifocal leukoencephalopathy in a patient post allo-HCT successfully treated with JC virus specific donor lymphocytes

Steinhardt MJ, Wiercinska E, Grigoleit GU, Mazzoni A, Da-Via M, Zhou X, Meckel K, Nickel K, Duell J, Krummenast FC, Kraus S, Hopkinson C, Weissbrich B, Müllges W, Stoll G , Kortüm KM, Einsele H, Bonig H, Rasche L
(2021) Neurol Neuroimmunol Neuroinflamm 8:e1020

Multivirus-specific T cells

Strategies of adoptive T -cell transfer to treat refractory viral infections post allogeneic stem cell transplantation.
Kaeuferle T, Krauss R, Blaeschke F, Willier S, Tobias Feuchtinger
(2019) J Hematol Oncol 12, 13

Automated production of specific T cells for treatment of refractory viral infections after allogeneic stem cell transplantation.
Heinz AT, Calkoen FGJ, Derbich A, Miltner L, Seitz C, Doering M, Braun C, Atar D, Schumm M, Heubach F, Arendt AM, Schulz A, Schuster FR, Meisel R, Strahm B, Finke J, Heineking B, Stetter S, Silling G, Stachel D, Gruhn B, Debatin KM, Foell J, Schulte JH, Woessmann W, Mauz-Körholz C, Tischer J, Feuchtinger T, Handgretinger R, Lang P.
Haematologica. 2023
doi:10.3324/haematol.2022.281996.

SARS-CoV-2-specific T cells

Effective virus-specific T-cell therapy for high-risk SARS-CoV-2 infections in hematopoietic stem cell transplant recipients: initial case studies and literature review
Gopcsa L, Réti M,·Andrikovics H, Bobek I, Bekő G, Bogyó J, Ceglédi A, Dobos K, Giba-Kiss L, Jankovics I, Kis O, Lakatos B, Mathiász D, Meggyesi N, Miskolczi G, Németh N, Paksi M, Riczu A, Sinkó J, Szabó B, Szilvási A, Szlávik J, Tasnády S, Reményi P, Vályi-Nagy I
GeroScience (2023).
https://doi.org/10.1007/s11357-023-00858-7

Pre-Clinical Data

SARS-CoV-2-specific T cells

Manufacture and Characterization of Good Manufacturing Practice-Compliant SARS-COV-2 Cytotoxic T Lymphocytes
Chu Y, Milner J, Lamb M, Cairo MS *et al.*
(2023) The Journal of Infectious Diseases; 227:788–799,

Rapid Manufacturing of Highly Cytotoxic Clinical-Grade SARS-CoV-2-specific T Cell Products Covering SARS-CoV-2 and Its Variants for Adoptive T Cell Therapy
Bonifacius A, Tischer-Zimmermann S, Santamorena M M, Mausberg P, Schenk J, Koch S, Barnstorf-Brandes J, Gödecke N, Martens J, Goudeva L, Verboom M, Wittig J, Maecker-Kolhoff B, Baurmann H, Clark C, Brauns O, Simon M, Lang P, Cornely O A, Hallek M, Blasczyk R, Seiferling D, Köhler P, Eiz-Vesper B
(2022) Frontiers in Bioengineering and Biotechnology; 10:Article 867042

Isolation of Functional SARS-CoV-2 Antigen-Specific T-Cells with Specific Viral Cytotoxic Activity for Adoptive Therapy of COVID-19
García-Ríos E, Leivas A, Mancebo FJ, Sánchez-Vega L, Lanzarot D, Aguado JM, Martínez-López J, Paciello L, Pérez-Romero P
(2022) Biomedicines 2022, 10:630

Rapid GMP-Compliant Expansion of SARS-CoV-2–Specific T Cells From Convalescent Donors for Use as an Allogeneic Cell Therapy for COVID-19
Cooper RS, Fraser AR, Smith L, Burgoyne P, Imlach SN, Jarvis LM, Turner DM, Zahra S, Turner ML, Campbell JDM
(2021) Front. Immunol. 11:598402.

Rapid production of clinical-grade SARS-CoV-2 specific T cells
Wing Leung, Teck Guan Soh, Yeh Ching Linn, Jenny Guek-Hong Low, Jiashen Loh, Marieta Chan, Wee Joo Chng, Liang Piu Koh, Michelle Li-Mei Poon, King Pan Ng, Chik Hong Kuick, Thuan Tong Tan, Lip Kun Tan, Michaela Su-fern Seng
(2020) Adv Cell Gene Ther., 2020;00:e101.

Multivirus-specific T cells

Effect of T cell subset dose on outcome of T cell-depleted bone marrow transplantation.

Kawanishi Y, Passweg J, Drobyski WR, Rowlings P, Cook-Craig A, Casper J, Pietryga D, Garbrecht F, Camitta B, Horowitz M, Juckett M, Margolis D, Flomenberg N, Keever-Taylor CA
(1997) Bone Marrow Transplant., 19:1069-77.

Singlevirus-specific T cells

CMV

Automated isolation of primary antigen-specific T cells from donor lymphocyte concentrates: results of a feasibility exercise.

Bunos M, Hümmer C, Wingenfeld E, Sorg N, Pfirrmann V, Bader P, Seifried E, Bönig H
(2015) Vox Sang., 109:387

Robust Production of Cytomegalovirus pp65-Specific T cells Using a Fully Automated IFN-γ Cytokine Capture System

Kim N, Nam YS, Keon-Il Im, Lim JY, Jeon YW, Song Y, Lee JW., Cho SG (2017)
(2017) Transfus Med Hemother., 44:1–10

Automated cell enrichment of cytomegalovirus-specific T cells for clinical applications using the cytokine-capture system.

Pappanaicken K, Figliola M, Moyes JS, Huls MH, Tewari P, Shpall EJ, Champlin RE, and Cooper LJN
(2015) J. Vis. Exp.; doi: 10.3791/52808; 1-10

Comparative Analysis of Clinical-scale IFN-γ-Positive T-Cell enrichment Using Partially and Fully Integrated Platforms.

Priesner C, Esser R, Tischer S, Marburger M, Aleksandrova K, Maecker-Kolhof B, Heuft HG, Goudeva L, Blasczyk R, Arseniev L, Köhl U, Eiz-Vesper B, Klöß S
(2016) Front. Immunol. 7:393.

Rapid generation of clinical-grade antiviral T cells: selection of suitable T-cell donors and GMP-compliant manufacturing of antiviral T cells

Tischer S, Priesner C, Heuft HG, Goudeva L, Mende W, Barthold M, Kloeß S, Arseniev L, Aleksandrova K, Maecker-Kolhoff B, Blasczyk R, Koehl U, Eiz-Vesper B
(2014) J. Translat. Med.;12:336.

HLA type-independent generation of antigen-specific T cells for adoptive immunotherapy.

Hammer MH, Meyer S, Brestrich G, Moosmann A, Kern F, Tesfa L, Babel N, Mittenzweig A, Rooney CM, Hammerschmidt W, Volk HD, Reinke P
(2005) Eur. J. Immunol., 35:250-8.

Rapid generation of combined CMV-specific CD4+ and CD8+ T-cell lines for adoptive transfer into recipients of allogeneic stem cell transplants.

Rauser G, Einsele H, Sinzger C, Wernet D, Kuntz G, Assenmacher M, Campbell JD, Topp MS
(2004) Blood, 103:3565-72.

Rapid detection, enrichment and propagation of specific T cell subsets based on cytokine secretion.

Campbell JDM, Foerster A, Lasmanowicz V, Niemöller M, Scheffold A, Fahrendorff M, Rauser G, Assenmacher M, Richter A
(2010) Clinical and Experimental Immunology, 163: 1–10

EBV

Generation of EBV-specific T cells for adoptive immunotherapy: A novel protocol using formalin-fixed stimulator cells to increase biosafety.

Hammer MH, Brestrich G, Mittenzweig A, Roemhild A, Zwinger S, Subklewe M, Beier C, Kurtz A, Babel N, Volk HD, Reinke P
(2007) J. Immunother.,30:817-24.

AdV

Rapid Generation of full clinical-grade human antiadenovirus cytotoxic T cells for adoptive immunotherapy.

Aïssi-Rothé L, Decot V, Venard V, Jeulin H, Salmon A, Clement L, Mathieu C, Rauser G, de Carvalho M, Stoltz JF, Bordigoni P, Bensoussan D

(2010) J. Immunother.,33:414-24.

Clinical grade generation of hexon-specific T cells for adoptive T-cell transfer as a treatment of adenovirus infection after allogeneic stem cell transplantation.

Feuchtinger T, Richard C, Joachim S, Scheible MH, Schumann M, Hamprecht K, Martin D, Jahn G, Handgretinger R, Lang P (2008) J. Immunother.,31:199-206.

Capture and generation of adenovirus specific T cells for adoptive immunotherapy.

Chatziandreou I, Gilmour KC, McNicol AM, Costabile M, Sinclair J, Cubitt D, Campbell JD, Kinnon C, Qasim W, Bobby Gaspar H
(2007) Br. J. Haematol., 136:117-26.

Adenovirus-specific T-cell Subsets in Human Peripheral Blood and After IFN-g Immunomagnetic Selection.

Qian C, Wang Y, Cai H, Laroye C, De Carvalho Bittencourt M, Clement L, Stoltz JF, Decot V, Reppel L, Bensoussan D
(2016) J Immunother;39:27–35

Fungus-specific T cells

Clinical-scale generation of human anti-Aspergillus T cells for adoptive immunotherapy.

Tramsen L, Koehl U, Tonn T, Latgé JP, Schuste, FR, Borkhardt A, Uharek L, Quaritsch R, Beck O, Seifried E, Klingebiel T, Lehrnbecher T (2009) Bone Marrow Transplant., 43:13-9.

Generation and characterization of anti-Candida T cells as potential immunotherapy in patients with candida infection after allogeneic hematopoietic stem-cell transplant.

Tramsen L, Beck O, Schuster FR, Hunfeld KP, Latgé JP, Sarfati J, Röger F, Klingebiel T, Koehl U, Lehrnbecher T
(2007) J. Infect. Dis., 196:485-92.

Generation of highly purified and functionally active human Th1 cells against Aspergillus fumigatus.

Beck O, Topp MS, Koehl U, Roilides E, Simitsopoulou M, Hanisch M, Sarfati J, Latgé JP, Klingebiel T, Einsele H, Lehrnbecher T (2006) Blood, 107:2562-9.

Tumor-specific T cells

Rapid generation of NY-ESO-1-specific CD4+ Thelper-1 cells for adoptive T-cell therapy

Kayser S, Boβ C, Feucht J, Witte KE, Scheu A, Bülow HJ, Joachim S, Stevanović S, Schumm M, Rittig SM, Lang P, Röcken M, Handgretinger R, Feuchtinger T
(2015) Oncoimmunol.;
4(5):DOI:10.1080/2162402X.2014.1002723

Early detection and rapid isolation of leukemia-reactive donor T cells for adoptive transfer using the IFN-g secretion assay.

Jedema I, Meij P, Steeneveld E, Hoogendoorn M, Nijmeijer BA, Willemze R, Falkenburg JH
(2007) Clin. Cancer Res., 13:636-43.

Review

Antigen-Specific T Cells and SARS-CoV-2 Infection: Current Approaches and Future Possibilities.

Nova Z, Zemanek T, Botek N.
(2022) International Journal of Molecular Sciences.; 23(23):15122.

Viral-specific T-cell transfer from HSCT donor for the treatment of viral infections or disease after HSCT.

Qian C, Wang Y, Reppel L, Dáveni M, Campidelli A, Decot V, Bensoussan D (2018) Bone Marrow Transplantation 53, 114-122

T cells for viral infections after allogeneic hematopoietic stem cell transplant.
Bollard CM, Heslop HE
(2016) Blood 127(26):3331-3340

Recent Developments in Cellular immunotherapy for HSCT-Associated Complications.

Reis M, Ogonek J, Qesari M,Borges NM, Nicholson L, Preußner L, Dickinson AM, Wang XN, Weissinger EM, Richter A
(2016) Front. Immunol. 7:500.

Improving T-cell therapy for Epstein-Barr Virus lymphoproliferative disorders.

Bollard CM
(2012) J. Clin. Oncol., 31:5-7

Rapid detection, enrichment and propagation of specific T cell subsets based on cytokine secretion.

Campbell JD, Foerster A, Lasmanowicz V, Niemöller M, Scheffold A, Fahrendorff M, Rauser G, Assenmacher M, Richter A
(2011) Clin Exp Immunol., 163:1-10

Pathogen specific T-lymphocytes for the reconstitution of the immunocompromised host.

Li Pira G, Kapp M, Manca F, Einsele H
(2009) Curr. Opin. Immunol., 21:549-56.

Adoptive T cell immunotherapy for cytomegalovirus.

Peggs K.
(2009) Expert. Opin. Biol. Ther., 9:725-36.

Miltenyi Biotec

Miltenyi Biotec provides products and services worldwide. Visit **www.miltenyibiotec.com/local** to find your nearest Miltenyi Biotec contact.